Changes of blood coagulation indicators in patients with lymphoplasmacytic lymphoma and their clinical significances
10.3760/cma.j.issn.1009-9921.2018.11.004
- VernacularTitle:淋巴浆细胞淋巴瘤患者凝血指标变化及其临床意义
- Author:
Yuxiang LIU
1
,
2
;
Yang CAO
;
Yue LIU
;
Quan GU
;
Weimin DONG
;
Xiaobao XIE
;
Bai HE
;
Feng YAN
;
Weiying GU
Author Information
1. 213003 苏州大学附属第三医院 常州市第一人民医院血液科
2. 213300 江苏省人民医院溧阳分院血液科
- Keywords:
Lymphoplasmacytic lymphoma;
Blood coagulation factors;
Platelets
- From:
Journal of Leukemia & Lymphoma
2018;27(11):656-659
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the alteration and clinical significances of blood coagulation indicators in patients with lymphoplasmacytic lymphoma (LPL). Methods Twenty patients who were newly diagnosed LPL in the First People's Hospital of Changzhou from January 2008 to October 2017 and twenty healthy controls were studied. The patients were treated by chemotherapy, plasma exchange, supplement of coagulation factor or other supportive therapy. The parameters of prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (FIB), thrombin time (TT), D-dimer (D-D), and platelet count (Plt) were detected in LPL group and healthy controls. Results The levels of PT and APTT in LPL group were dramatically higher than those in control group [(12.9±1.2) s vs. (11.6±0.9) s, (41.7±9.8) s vs. (24.7±2.9) s], and the level of Plt in LPL group was lower than that in control group [112×109/L (3×109/L - 379×109/L) vs. 210×109/L (170×109/L - 271×109/L)], and the differences were statistically significant (all P< 0.05). There were no significant differences in FIB, TT and D-D levels between LPL group and control group (all P ＞0.05). There were no statistical differences in PT, APTT, FIB, TT, D-D and Plt levels among LPL patients with different types of immunoglobins (all P ＞ 0.05). After treatment, all the coagulation abnormalities got relieved and no patient died of hemorrhage or thrombosis. Conclusions The LPL patients have coagulation disorders and hypercoagulability, and this is independent of the type of immunoglobulin. Clinical attention should be paid to monitoring coagulation indicators to prevent the occurrence of adverse reactions.
